ArticleScientific reports2026
Experiences and theory reveal a decrease in antimicrobial blue light killing efficiency as biofilm grows in a Pseudomonas aeruginosa model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recently, the use of antimicrobial blue light (aBL) has gained interest across various applications. However, a comprehensive framework that addresses the key factors driving bacterial photoinhibition remains lacking-particularly concerning biofilms, the predominant bacterial lifestyle. The goal of this work was to evaluate the potential of photokilling in this wide-spread microbial adherent community type, and to decipher the specific mechanisms at stake. To investigate aBL killing efficiency, we conducted experiments in a Pseudomonas aeruginosa biofilm model using a well-defined millifluidic device that allows real-time microscopy and quantitative analysis of a living biofilm under local irradiation at a defined light dose. In addition, we developed a theoretical model for light-biofilm interaction that accounts for the three-dimensional structure of the bacterial biofilm. To inform our model, we examined the light dose-response in isolated cells and found a profile indicative of a multi-target mechanism of lethality. By comparing the experimental and theoretical results, we identified a loss in killing efficiency as the biofilm grows, due in part to the increase in thickness of the living material inherent to this mode of development. Our findings also highlight a reduction in the intrinsic bacterial sensitivity to blue light as biofilm development progresses, which we attribute to the low oxygen levels typical of densely populated bacterial environments. These findings reveal new features of the photokilling mechanism and redefine the approach to designing effective antimicrobial photoinactivation strategies by integrating the key physical characteristics of bacterial biofilms. Awareness of the bacterial world's global importance is steadily growing in both science and society. Among the critical challenges, the continuing increase in multidrug resistance to antibiotics represents a major public health concern reinforcing the urgency of alternative antimicrobial therapies with photoinactivation as a promising approach. However, its full potential can only be achieved through a better understanding of the involved mechanisms in relevant environments. In this study, we combined experimental and theoretical approaches to investigate the photoinactivation of bacteria within a developing biofilm, the dominant bacterial lifestyle. Our comprehensive analysis sheds light on the mechanisms and limitations of photoinactivation in the fight against microbes, which is essential for designing novel antibacterial phototherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.